Free Trial

Cartesian Therapeutics (RNAC) Competitors

Cartesian Therapeutics logo
$10.02 -0.02 (-0.21%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RNAC vs. PHAR, TRVI, ATAI, SPRY, CRON, CRMD, UPB, SYRE, QURE, and URGN

Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Pharming Group (PHAR), Trevi Therapeutics (TRVI), atai Life Sciences (ATAI), ARS Pharmaceuticals (SPRY), Cronos Group (CRON), CorMedix (CRMD), Upstream Bio (UPB), Spyre Therapeutics (SYRE), uniQure (QURE), and Urogen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.

Cartesian Therapeutics vs. Its Competitors

Cartesian Therapeutics (NASDAQ:RNAC) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Cartesian Therapeutics presently has a consensus target price of $40.00, indicating a potential upside of 299.24%. Pharming Group has a consensus target price of $30.00, indicating a potential upside of 100.07%. Given Cartesian Therapeutics' higher possible upside, equities analysts clearly believe Cartesian Therapeutics is more favorable than Pharming Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Pharming Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Pharming Group has higher revenue and earnings than Cartesian Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cartesian Therapeutics$38.91M6.69-$77.42M-$52.83-0.19
Pharming Group$297.20M3.46-$11.84M-$0.13-115.35

87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cartesian Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -2.19%. Cartesian Therapeutics' return on equity of 0.00% beat Pharming Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cartesian TherapeuticsN/A N/A -6.36%
Pharming Group -2.19%-3.31%-1.78%

In the previous week, Pharming Group had 2 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 3 mentions for Pharming Group and 1 mentions for Cartesian Therapeutics. Pharming Group's average media sentiment score of 0.75 beat Cartesian Therapeutics' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cartesian Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Pharming Group
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cartesian Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500.

Summary

Cartesian Therapeutics beats Pharming Group on 9 of the 16 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNAC vs. The Competition

MetricCartesian TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$259.61M$3.16B$5.77B$10.50B
Dividend YieldN/A2.36%5.61%4.58%
P/E Ratio-0.1921.2076.9527.03
Price / Sales6.69452.67553.80128.22
Price / CashN/A44.8325.8131.15
Price / Book-37.119.8713.886.54
Net Income-$77.42M-$52.82M$3.30B$271.76M
7 Day Performance4.36%3.92%2.46%3.85%
1 Month Performance-10.78%6.24%4.90%8.34%
1 Year Performance-32.62%17.73%83.63%27.26%

Cartesian Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNAC
Cartesian Therapeutics
1.6056 of 5 stars
$10.02
-0.2%
$40.00
+299.2%
-37.4%$259.61M$38.91M-0.1964
PHAR
Pharming Group
2.0159 of 5 stars
$13.72
-6.6%
$30.00
+118.7%
+95.5%$1.01B$297.20M-105.50280
TRVI
Trevi Therapeutics
1.9824 of 5 stars
$8.06
-2.3%
$21.75
+169.9%
+148.5%$1.00BN/A-19.1920
ATAI
atai Life Sciences
3.1322 of 5 stars
$4.65
+0.4%
$11.25
+141.9%
+300.0%$992.39M$310K-6.7480News Coverage
SPRY
ARS Pharmaceuticals
2.6265 of 5 stars
$9.96
-0.7%
$32.50
+226.3%
-33.7%$991.23M$89.15M-20.3390
CRON
Cronos Group
2.5317 of 5 stars
$2.55
+0.8%
N/A+20.5%$968.72M$130.28M51.00450
CRMD
CorMedix
3.8389 of 5 stars
$12.65
-2.2%
$18.00
+42.3%
+52.7%$965.96M$43.47M16.8730Gap Up
UPB
Upstream Bio
1.5214 of 5 stars
$16.79
-4.4%
$56.50
+236.5%
N/A$947.19M$2.37M0.0038Positive News
SYRE
Spyre Therapeutics
2.2978 of 5 stars
$14.84
-5.2%
$53.40
+259.8%
-49.3%$945.28MN/A-4.3673Analyst Downgrade
High Trading Volume
QURE
uniQure
2.8428 of 5 stars
$14.84
-10.0%
$37.45
+152.4%
+158.0%$904.48M$27.12M-3.79500High Trading Volume
URGN
Urogen Pharma
4.1027 of 5 stars
$18.06
-3.9%
$32.00
+77.2%
+32.9%$869.30M$90.40M-5.44200Positive News

Related Companies and Tools


This page (NASDAQ:RNAC) was last updated on 9/23/2025 by MarketBeat.com Staff
From Our Partners